We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhanced Prescription Drug Label to Improve Patient Understanding and Use

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00973180
First Posted: September 9, 2009
Last Update Posted: September 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Michael S. Wolf, Northwestern University
  Purpose

The overall objective of this study is to test the efficacy of an evidence-based, enhanced Rx container label design to improve patients' understanding of instructions for use.

The investigators will conduct a randomized controlled trial (N=960) to evaluate the efficacy of the enhanced Rx container label to improve patients' understanding of actual prescribed medicines, compared to a standard label format. Patients with type II diabetes and/or hypertension at safety-net clinics affiliated with one central-fill pharmacy (Nova Scripts Central - NSC) receive their prescribed medicines from this location. Recruited subjects in this study will be randomly assigned to either intervention (enhanced Rx container label) or control (standard Rx label). All pill-form, regular dosing schedule medicines, including diabetes and hypertensive (i.e. ACE inhibitor) medicines associated with patients' treatment will be labeled according to study arm by the central-fill pharmacy. Study subjects will be interviewed at the time of dispensing the prescribed medicines at the clinic, again three months later (dispensing of refill), and finally nine months after baseline (dispensing of refill). Pharmacy refill data and medical record information - linked at these clinics - will be collected for exploratory analyses. Patients' ability to read and demonstrate Rx label instructions, including auxiliary warnings, will be the primary outcomes. Other exploratory outcome measures will also be measured, including 1) adverse effects associated with medication use defined by a) the rate of physician visits, b) the rate of emergency room visits, and c) the rate of hospitalizations and hospital admissions via emergency rooms for medication side effects (e.g. hyperglycemia or hypoglycemia); and 2) health outcome as measured by the change from baseline in hemoglobin A1c (HbA1c) and blood pressure measurements. Data from the actual use trial will be processed, reviewed, analyzed (in order of hypotheses), and reports prepared during the final months of this last phase of the study.


Condition Intervention
Prescription Medication Understanding Other: Enhanced Label

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Enhanced Prescription Drug Label to Improve Patient Understanding and Use

Further study details as provided by Michael S. Wolf, Northwestern University:

Primary Outcome Measures:
  • Understanding of prescription medication [ Time Frame: Baseline, 3 months, 9 months ]

Secondary Outcome Measures:
  • Change in HbA1c or blood pressure readings [ Time Frame: Baseline, 3 months, 9 months ]

Enrollment: 850
Study Start Date: May 2009
Study Completion Date: January 2013
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enhanced Label
Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
Other: Enhanced Label
A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
No Intervention: Standard Label
Subjects in this arm will receive their prescriptions labeled with a standard label.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Type II diabetes or hypertension in their medical chart.
  • 30 years or older.
  • Fluent in English.

Exclusion Criteria:

  • Uncorrectable hearing or visual impairment.
  • Too ill to participate.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00973180


Locations
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Investigators
Principal Investigator: Michael S. Wolf, PhD, MPH Northwestern University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael S. Wolf, Professor, Northwestern University
ClinicalTrials.gov Identifier: NCT00973180     History of Changes
Other Study ID Numbers: NU-0923017
First Submitted: September 8, 2009
First Posted: September 9, 2009
Last Update Posted: September 29, 2014
Last Verified: September 2014

Keywords provided by Michael S. Wolf, Northwestern University:
Prescription medication understanding among diabetic and hypertension patients.
Prescription medication use among diabetic and hypertension patients.
Hemoglobin A1c changes among diabetic patients.
Blood pressure changes among hypertension patients.